Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Emerson Electric (NYSE: EMR), the St. Louis-based industrial technology and software company, unveiled its new corporate ...

American architecture studio Gensler has revealed designs for an office-to-residential conversion of the former Pfizer ...

A new report from Gensler and the Pew Charitable Trust proposes converting old office buildings into SRO-style housing.

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

The best office chair offers better ergonomics, all-day comfort, lumbar support, and smart designs to suit every workspace. My team and I tested over 50 different desk chairs, including task ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

However, one field has witnessed a significant transformation in the hands of AI designers. Artificial Intelligence in design is not just about replacing human designers; it enhances their abilities ...

Can't decide between Microsoft 365 or Office 2024 for school or work? In this guide, we'll help you pick the best option for you. When you purchase through links on our site, we may earn an ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...